Nonexcitatory electrical signals for enhancing ventricular contractility: Rationale and initial investigations of an experimental treatment for heart failure

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 288, Issue 6 57-6, 2005, Pages

  Burkhoff, Daniel ^a,b,c,d   Ben Haim, Shlomo A ^b,e  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b IMPULSE Dynamics Incorporated   (United States)

^c Columbia University Medical School ^*  (United States)

^d IMPULSE Dynamics   (United States)

^e TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ION; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CALCIUM SIGNALING; CALCIUM TRANSPORT; CARDIAC RESYNCHRONIZATION THERAPY; EDITORIAL; ELECTRIC CONDUCTIVITY; EXCITATION CONTRACTION COUPLING; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE CONTRACTILITY; HOSPITALIZATION; HUMAN; INOTROPISM; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION; SURVIVAL RATE;

ANIMALS; ELECTRIC COUNTERSHOCK; ELECTROPHYSIOLOGY; HEART; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HUMANS; MYOCARDIAL CONTRACTION;

EID: 19344367771     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.01311.2004     Document Type: Editorial

References (76)

1. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, and Messenger J, Cardiac resynchronization in chronic heart failure. N Engl J Med 346: 1845-1853, 2002.
2. Adams KF Jr. New epidemiologic perspectives concerning mild-to-moderate heart failure. Am J Med 110, Suppl 7A: 6S-13S, 2001.
3. Auricchio A and Abraham WT. Cardiac resynchronization therapy: current state of the art: cost versus benefit. Circulation 109: 300-307, 2004.
4. Auricchio A, Stellbrink C, Butter C, Sack S, Vogt J, Misier AR, Bocker D, Block M, Kirkels JH, Kramer A, and Huvelle E. Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. J Am Coll Cardiol 42: 2109-2116, 2003,
5. Bagger JP, Botker HE, Thomassen A, and Nielsen TT. Effects of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease. Cardiovasc Drugs Ther 11: 479-484, 1997.
6. Barbone A, Holmes JW, Heerdt PM, The' AH, Naka Y, Joshi N, Daines M, Marks AR, Oz MC, and Burkhoft D. Comparison of right and left ventricular responses to left ventricular assist device support in patients with severe heart failure: a primary role of mechanical unloading underlying reverse remodeling. Circulation 104: 670-675, 2001.
7. Bers DM. Cardiac excitation-contraction coupling. Nature 415: 198-205, 2002.
8. Braunwald E. Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 337: 1360-1369, 1997.
9. Bristow MR. β-Adrenergic receptor blockade in chronic heart failure. Circulation 101: 558-569, 2000.
10. Bristow MR, Feldman AM, and Saxon LA. Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investigators. J Card Fail 6: 276-285, 2000.
11. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, and Feldman AM. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350: 2140-2150, 2004.
12. Brunckhorst C, Shemer I, Mika Y, Ben-Haim SA, and Burkhoff D. Cardiac contractility modulation by non-excitatory currents: studies in isolated cardiac muscle. Eur J Heart Failure. In press.
13. Burkhoff D, Oikawa RY, and Sagawa K. Influence of pacing site on canine left ventricular contraction. Am J Physiol Heart Circ Physiol 251: H428-H435, 1986.
14. Burkhoff D, Shemer I, Felzen B, Shimizu J, Mika Y, Dickstein M, Prutchi D, Darvish N, and Ben-Haim SA. Electric currents applied during the refractory period can modulate cardiac contractility in vitro and in vivo. Heart Fail Rev 6: 27-34, 2001.
15. Burkhoff D, Weiss RG, Schulman SP, Kalil-Filho R, Wannenburg T, and Gerstenblith G. Influence of metabolic substrate on rat heart function and metabolism at different coronary flows. Am J Physiol Heart Circ Physiol 261: H741-H750, 1991.
16. Chandler MP, Stanley WC, Morita H, Suzuki G, Roth BA, Blackburn B, Wolff A, and Sabbah HN. Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ Res 91: 278-280, 2002.
17. Chung ES, Packer M, Lo KH, Fasanmade AA, and Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107: 3133-3140, 2003.
18. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong and M. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325: 303-310, 1991.
19. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, and Wright TJ. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 5: 659-667, 2003.
20. Cohn JN and Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667-1675, 2001.
21. Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 80: 15L-25L, 1997.
22. Conti CR. Partial fatty acid oxidation (pFOX) inhibition: a new therapy for chronic stable angina. Clin Cardiol 26: 161-162, 2003.
23. Curry CW, Nelson GS, Wyman BT, Declerck J, Talbot M, Berger RD, McVeigh ER, and Kass DA. Mechanical dyssynchrony in dilated cardiomyopathy with intraventricular conduction delay as depicted by 3D tagged magnetic resonance imaging. Circulation 101: E2, 2000.
24. Dorn GW and Molkentin JD. Manipulating cardiac contractility in heart failure: data from mice and men. Circulation 109: 150-158, 2004.
25. Feldman AM, Baughman KL, and Strobeck JE. Oral milrinone in severe chronic heart failure. N Engl J Med 326: 1565-1566, 1992.
26. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, and Bain RP. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med 329: 149-155, 1993.
27. Feldman AM, Weinberg EO, Ray PE, and Lorell BH. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circ Res 73: 184-192, 1993.
28. 2+-calcineurin-NFAT cascade in cardiac myocytes. Cardiovasc Res 63: 450-457, 2004.
29. Foody JM, Farrell MH, and Krumholz HM. β-Blocker therapy in heart failure: scientific review. JAMA 287: 883-889, 2002.
30. Frank K and Kranias EG. Phospholamban and cardiac contractility. Ann Med 32: 572-578, 2000.
31. Frank KF, Bolck B, Brixius K, Kranias EG, and Schwinger RH. Modulation of SERCA: implications for the failing human heart. Basic Res Cardiol 97, Suppl 1: 172-178, 2002.
32. Gomez AM, Valdivia HH, Cheng H, Lederer MR, Santana LF, Cannell MB, McCune SA, Altschuld RA, and Lederer WJ. Defective excitation-contraction coupling in experimental heart failure. Science 276: 800-806, 1997.
33. Gupta RC, Mishra S, Rastogi S, Imai M, Hadad W, Mika Y, and Sabbah HN. Non-excitatory cardiac contractility modulation electric signals normalize phosphorylation and expression of the sodium calcium exchanger in left ventricular myocardium of dogs with heart failure (Abstract). Eur Heart J 25: 1116, 2004.
34. Gupta RC, Mishra S, Rastogi S, Imai M, Haddad W, Mika Y, and Sabbah HN. Short-term therapy with non-excitatory modulation electric signals increases phosphorylation of phospholamban in left ventricular myocardium of dogs with chronic heart failure (Abstract), Eur Heart J 25: 1116. 2004.
35. Gupta RC, Mishra S, Sharad R, Imai M, Haddad W, Mika Y, and Sabbah HN. Non-excitatory cardiac contractility modulation electric signals normalize phosphorylation and expression of the sodium calcium exchanger in left ventricular myocardium of dogs with heart failure (Abstract). J Am Coll Cardiol. In press.
36. Haghighi K, Gregory KN, and Kranias EG. Sarcoplasmic reticulum Ca-ATPase-phospholamban interactions and dilated cardiomyopathy. Biochem Biophys Res Commun 322: 1214-1222, 2004.
37. 2+-ATPase in failing and nonfailing human myocardium. Circ Res 75: 434-442, 1994.
38. Heerdt PM, Holmes JW, Cai B, Barbone A, Madigan JD, Reiken S, Lee DL, Oz MC, Marks AR, and Burkhoff D. Chronic unloading by left ventricular assist device reverses contractile dysfunction and alters gene expression in end-stage heart failure. Circulation 102: 2713-2719, 2000.
39. Klotz S, Barbone A, Reiken S, Holmes JW, Naka Y, Oz MC, Marks AR, and Burkhoff D. Left ventricular assist device support normalizes left and right ventricular β-adrenergic pathway properties. J Am Coll Cardiol. In press.
40. Li Y, Kranias EG, Mignery GA, and Bers DM. Protein kinase A phosphorylation of the ryanodine receptor does not affect calcium sparks in mouse ventricular myocytes. Circ Res 90: 309-316, 2002.
41. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91: 988-998, 2002.
42. Mann DL. Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol 65: 81-101, 2003.
43. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, Van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, and Fleming T. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109: 1594-1602, 2004.
44. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, and Marks AR. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101: 365-376, 2000.
45. 45a. Metoprolol CR/XL Randomized Intervention Trial. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353: 2001-2007, 1999.
46. Mishra S, Gupta RC, Haddad W, Rastogi S, Imai M, Mika Y, and Sabbah HN. Therapy with non-excitatory cardiac contractility modulation electrical signals partially restores mRNA expression of connexin 43 in left ventricular myocardium of dogs with heart failure (Abstract). J Card Fail 10: 153, 2004.
47. Mishra S, Gupta RC, Rastogi S, Haddad W, Mika Y, and Sabbah HN. Short-term therapy with nonexcitatory cardiac contractility modulation electric signals increases phosphorylation of phospholamban in left ventricular myocardium of dogs with chronic heart failure (Abstract). Circulation 110: III-604. 2004.
48. 2+ uptake in human failing left ventricular myocardium. J Heart Lung Transplant 21: 366-373, 2002.
49. Mohri S, He KL, Dickstein M, Mika Y, Shimizu J, Shemer I, Yi GH, Wang J, Ben-Haim S, and Burkhoff D. Cardiac contractility modulation by electric currents applied during the refractory period. Am J Physiol Heart Circ Physiol 282: H1642-H1647, 2002.
50. Mohri S, Shimizu J, Mika Y, Shemer I, Wang J, Ben-Haim S, and Burkhoff D. Electric currents applied during the refractory period enhance contractility and systolic calcium in the ferret heart. Am J Physiol Heart Circ Physiol 284: H1119-H1123, 2003.
51. Morita H, Suzuki G, Haddad W, Mika Y, Tanhehco EJ, Sharov VG, Goldstein S, Ben-Haim S, and Sabbah HN. Cardiac contractility modulation with nonexcitatory electric signals improves left ventricular function in dogs with chronic heart failure. J Card Fail 9: 69-75, 2003.
52. Nelson GS, Berger RD, Fetics BJ, Talbot M, Hare JM, Kass DA, and Spinelli JC. Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. Circulation 102: 3053-3059, 2000.
53. O'Rourke B, Kass DA, Tomaselli GF, Kaab S, Tunin R, and Marban E. Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, I: experimental studies. Circ Res 84: 562-570, 1999.
54. Packer M. Neurohormonal interactions and adaptations in congestive heart failure. Circulation 11: 721-730, 1988.
55. Packer M. Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure. Am J Cardiol 63: 41A-45A, 1989.
56. Packer M. Role of the sympathetic nervous system in chronic heart failure: a historical and philosophical perspective. Circulation 82, Suppl I: I1-I6. 1990.
57. Packer M. The development of positive inotropic agents for chronic heart failure: how have we gone astray? J Am Coll Cardiol 22: 119A-126A, 2000.
58. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, and Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U S Carvedilol Heart Failure Study Group. N Engl J Med 334: 1349-1355, 1996.
59. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, and Kukin ML. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325: 1468-1475, 1991.
60. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, and DeMets DL. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344: 1651-1658, 2001.
61. Pappone C, Augello G, Rosanio S, Vicedomini G, Santinelli V, Romano M, Agricole E, Maggi F, Buchmayr G, Moretti G, Mika Y, Ben-Haim SA, Wolzt M, Stix G, and Schmidinger H. First human chronic experience with cardiac contractility modulation by nonexcitatory electrical currents for treating systolic heart failure: mid-term safety and efficacy results from a multicenter study. J Cardiovasc Electrophysiol 15: 418-427, 2004.
62. Pappone C, Rosanio S, Burkhoff D, Mika Y, Vicedomini G, Augello G, Shemer I, Prutchi D, Haddad W, Aviv R, Snir Y, Kronzon I, Alfieri O, and Ben-Haim SA. Cardiac contractility modulation by electric currents applied during the refractory period in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 90: 1307-1313, 2002.
63. Pappone C, Vicedomini G, Loricchio ML, Meloni C, Salvati A, Kimchy Y, Hadad W, Aviv R, Mika Y, Darvish N, Kronzon I, and Ben-Haim SA. First clinical experience demonstrating improvement of hemodynamic parameters in heart failure patients through the application of non-excitatory electrical signals (Abstract). J Am Coll Cardiol 35, Suppl A: A-229, 2000.
64. Pappone C, Vicedomini G, Salvati A, Meloni C, Haddad W, Aviv R, Mika Y, Darvish N, Kimchy Y, Shemer I, Snir Y, Pruchi D, Ben-Haim SA, and Kronzon I. Electrical modulation of cardiac contractility: clinical aspects in congestive heart failure. Heart Fail Rev 6: 55-60, 2001.
65. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, and Pocock S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362: 759-766, 2003.
66. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, and Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321, 2003.
67. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Palensky J, and Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717, 1999.
68. Rastogi S, Mishra S, Habib O, Imai M, Gupta RC, Haddad W, Mika Y, Stanley WC, and Sabbah HN. Therapy with non-excitatory cardiac contractility modulation electric signals reverses the maladaptive fetal gene program in LV myocardium of dogs with heart failure (Abstract). Circulation 108: IV-444, 2003.
69. Reiken S, Wehrens XH, Vest JA, Barbone A, Klotz S, Mancini D, Burkhoff D, and Marks AR. Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation 107: 2459-2466, 2003.
70. Sabbah HN, Imai M, Haddad W, Habib O, Stanley WC, Chandler MP, and Mika Y. Non-excitatory cardiac contractility modulation electric signals improve left ventricular function in dogs with heart failure without increasing myocardial oxygen consumption (Abstract). Heart Rhythm 1: S181, 2004.
71. 2+-ATPaSe activity and phosphorylation level of phospholamban. Am J Physiol Heart Circ Physiol 277: H474-H480, 1999.
72. 2+-sensitivity of SERCA 2a in failing human myocardium due to reduced serine-16 phospholamban phosphorylation. J Mol Cell Cardiol 31: 479-491, 1999.
73. Stix G, Borggrefe M, Wolpert C, Hindricks G, Kottkamp H, Bocker D, Wichter T, Mika Y, Ben-Haim S, Burkhoff D, Wolzt M, and Schmidinger H. Chronic electrical stimulation during the absolute refractory period of the myocardium improves severe heart failure. Eur Heart J 25: 650-655, 2004.
74. 2+ exchanger in end-stage human heart failure. Circ Res 75: 443-453, 1994.
75. Wehrens XH, Lehnart SE, and Marks AR. Intracellular calcium release channels and cardiac disease. Annu Rev Physiol Jul 21, 2004; Epub ahead of print.
76. Wood EH, Heppner RL, and Weidmann S. Inotropic effects of electric currents: 1. Positive and negative effects of constant electric currents or current pulses applied during cardiac action potential. Circ Res 24: 409-445, 1969.